Skip to main content

Agile Therapeutics Value Stock - Dividend - Research Selection

Agile Therapeutics

ISIN: US00847L1008, WKN: A1135H

Market price date: 25.09.2020
Market price: 2,88 USD




Agile Therapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2020
Cash flow
Net operating cash flow -15.689.000
Capital Expenditures -98.000
Free cash flow -15.787.000
Balance sheet
Total Equity 45.745.000
Liabilities & Shareholders equity 49.540.000
Income statement
Net income -18.606.000
Eps (diluted) -0,380
Diluted shares outstanding 48.963.200
Net sales/revenue 100

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C -8,99
   
P/FC -8,93
Balance sheet
ROI-37,56
ROE92,34
Income statement
P/E-7,58
Div. Yield0,00%
P/B3,08
P/S1.410.140,16


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolAGRX
Market Capitalization141.014.016,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internethttp://www.agiletherapeutics.com


Description of the company

Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.agiletherapeutics.com